Abstract :
Ovarian cancer remains one of the leading causes of gynecological cancer mortality, with most patients presenting at advanced stages and facing poor prognosis. While conventional chemotherapy forms the backbone of treatment, it is often associated with significant adverse effects and suboptimal cure rates. Metronomic chemotherapy, characterized by frequent administration of lower doses of chemotherapeutic agents, has emerged as a promising alternative strategy. This approach potentially offers reduced toxicity while maintaining therapeutic efficacy through continuous drug exposure and anti-angiogenic effects. We present a series of four cases of advanced ovarian cancer treated with metronomic chemotherapy using tamoxifen and etoposide. The patients, aged 39-65 years, achieved complete remission and maintained disease-free status during long-term follow-up ranging from 5-10 years, as confirmed by serial CA-125 measurements and imaging studies. These cases demonstrate the potential utility of metronomic chemotherapy as a viable treatment option in advanced ovarian cancer, particularly in resource-limited settings. Our findings contribute to the growing evidence supporting the role of metronomic chemotherapy in gynecological oncology and warrant further investigation through larger, prospective studies.
Keyword :
Ovarian cancer, Chemotherapy, Tamoxifen, Etoposide